CTX310 vs Solbinsiran

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Atherosclerotic Cardiovascular Disease

Shared mechanism: ANGPTL3 · full Atherosclerotic Cardiovascular Disease pipeline

CTX310

Developed by CRISPR Therapeutics

Phase 1 in Atherosclerotic Cardiovascular Diseasegene editing (CRISPR-Cas9)
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: June 2027 · NCT07491172 (registry estimate)

No aligned efficacy figure on record for this race.

Solbinsiran

Developed by Eli Lilly

Phase 2 in Atherosclerotic Cardiovascular DiseaseRNAi (siRNA)
Partial signal

NCT05256654 · Phase 2 · completed

The study randomized 205 participants to three solbinsiran doses or placebo and masked both participants and investigators. Its primary endpoint was a laboratory biomarker rather than a hard clinical outcome, and the ApoB comparison was mixed across doses: significant for 400 mg but not for 100 mg or 800 mg, supporting moderate evidence rather than the highest grade.

Next expected readout: March 2027 · NCT07269210 (registry estimate)

Reported efficacy

Percent Change From Baseline for Apolipoprotein B (ApoB) at Day 180 (Baseline, Day 180): Percent Change From Baseline for Apolipoprotein B (ApoB) at Day 180 (Baseline, Day 180): LY3561774 100 mg -14.1% (Standard Error 4.98) | LY3561774 400 mg -24.3% (Standard Error 3.1) | LY3561774 800 mg -19% (Standard Error 3.35) vs Placebo -11.6% (Standard Error 3.65) (mixed)

Result source: NCT05256654

Results for Atherosclerotic Cardiovascular Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointCTX310Solbinsiran
LDL-C, % change—Not reported-17.5% vs -12.7%−4.8 vs placebo800 mg · wk 38.6 · n 59NCT05256654
5 other results
  • -19.7% vs -8.7% 800 mg · wk 25.7 · n 59 · Phase 2 · secondary NCT05256654
  • -21% vs -12.7% 400 mg · wk 38.6 · n 58 · Phase 2 · secondary NCT05256654
  • -24% vs -8.7% 400 mg · wk 25.7 · n 58 · Phase 2 · secondary NCT05256654
  • -7.1% vs -12.7% 100 mg · wk 38.6 · n 30 · Phase 2 · secondary NCT05256654
  • -9.9% vs -8.7% 100 mg · wk 25.7 · n 30 · Phase 2 · secondary NCT05256654
Non-HDL-C, % change—Not reported-27.3% vs -9.8%−17.5 vs placebo800 mg · wk 38.6 · n 59NCT05256654
5 other results
  • -31.5% vs -10.2% 800 mg · wk 25.7 · n 59 · Phase 2 · secondary NCT05256654
  • -27.6% vs -9.8% 400 mg · wk 38.6 · n 58 · Phase 2 · secondary NCT05256654
  • -33.1% vs -10.2% 400 mg · wk 25.7 · n 58 · Phase 2 · secondary NCT05256654
  • -13.5% vs -9.8% 100 mg · wk 38.6 · n 30 · Phase 2 · secondary NCT05256654
  • -19.8% vs -10.2% 100 mg · wk 25.7 · n 30 · Phase 2 · secondary NCT05256654
ApoB, % change—Not reported-19% vs -11.6%−7.4 vs placebo800 mg · wk 25.7 · n 59NCT05256654
5 other results
  • -24.3% vs -11.6% 400 mg · wk 25.7 · n 58 · Phase 2 · primary NCT05256654
  • -14.1% vs -11.6% 100 mg · wk 25.7 · n 30 · Phase 2 · primary NCT05256654
  • -19.4% vs -9.5% 800 mg · wk 38.6 · n 59 · Phase 2 · secondary NCT05256654
  • -19.7% vs -9.5% 400 mg · wk 38.6 · n 58 · Phase 2 · secondary NCT05256654
  • -19.2% vs -9.5% 100 mg · wk 38.6 · n 30 · Phase 2 · secondary NCT05256654
Lp(a), % change—Not reported—Not reported
3-point MACE (% with event)—Not reported—Not reported

LDL-C, % change

CTX310
—Not reported
Solbinsiran
-17.5% vs -12.7%−4.8 vs placebo800 mg · wk 38.6 · n 59NCT05256654
5 other results
  • -19.7% vs -8.7% 800 mg · wk 25.7 · n 59 · Phase 2 · secondary NCT05256654
  • -21% vs -12.7% 400 mg · wk 38.6 · n 58 · Phase 2 · secondary NCT05256654
  • -24% vs -8.7% 400 mg · wk 25.7 · n 58 · Phase 2 · secondary NCT05256654
  • -7.1% vs -12.7% 100 mg · wk 38.6 · n 30 · Phase 2 · secondary NCT05256654
  • -9.9% vs -8.7% 100 mg · wk 25.7 · n 30 · Phase 2 · secondary NCT05256654

Non-HDL-C, % change

CTX310
—Not reported
Solbinsiran
-27.3% vs -9.8%−17.5 vs placebo800 mg · wk 38.6 · n 59NCT05256654
5 other results
  • -31.5% vs -10.2% 800 mg · wk 25.7 · n 59 · Phase 2 · secondary NCT05256654
  • -27.6% vs -9.8% 400 mg · wk 38.6 · n 58 · Phase 2 · secondary NCT05256654
  • -33.1% vs -10.2% 400 mg · wk 25.7 · n 58 · Phase 2 · secondary NCT05256654
  • -13.5% vs -9.8% 100 mg · wk 38.6 · n 30 · Phase 2 · secondary NCT05256654
  • -19.8% vs -10.2% 100 mg · wk 25.7 · n 30 · Phase 2 · secondary NCT05256654

ApoB, % change

CTX310
—Not reported
Solbinsiran
-19% vs -11.6%−7.4 vs placebo800 mg · wk 25.7 · n 59NCT05256654
5 other results
  • -24.3% vs -11.6% 400 mg · wk 25.7 · n 58 · Phase 2 · primary NCT05256654
  • -14.1% vs -11.6% 100 mg · wk 25.7 · n 30 · Phase 2 · primary NCT05256654
  • -19.4% vs -9.5% 800 mg · wk 38.6 · n 59 · Phase 2 · secondary NCT05256654
  • -19.7% vs -9.5% 400 mg · wk 38.6 · n 58 · Phase 2 · secondary NCT05256654
  • -19.2% vs -9.5% 100 mg · wk 38.6 · n 30 · Phase 2 · secondary NCT05256654

Lp(a), % change

CTX310
—Not reported
Solbinsiran
—Not reported

3-point MACE (% with event)

CTX310
—Not reported
Solbinsiran
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

CTX310: no structured comparison results are available for Atherosclerotic Cardiovascular Disease.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. CTX310: 0 of 4 rows · Solbinsiran: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricSolbinsiran
Dropout rate
8.5%800 mg
NCT05256654 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease, Hypertriglyceridemia · phase 2
show 2 more results
5.2%400 mg
NCT05256654 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease, Hypertriglyceridemia · phase 2
10%100 mg
NCT05256654 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease, Hypertriglyceridemia · phase 2
Discontinued due to AEs
0%800 mg
NCT05256654 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease, Hypertriglyceridemia · phase 2
show 2 more results
1.7%400 mg
NCT05256654 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease, Hypertriglyceridemia · phase 2
0%100 mg
NCT05256654 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease, Hypertriglyceridemia · phase 2
Serious AEs
3.4%800 mg
NCT05256654 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease, Hypertriglyceridemia · phase 2
show 2 more results
5.2%400 mg
NCT05256654 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease, Hypertriglyceridemia · phase 2
3.3%100 mg
NCT05256654 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease, Hypertriglyceridemia · phase 2
Most frequent reported AEs
800 mg
covid-19 3.4% (placebo 7%)
hypertension 3.4% (placebo 3.5%)
influenza 3.4% (placebo 0%)
NCT05256654 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease, Hypertriglyceridemia · phase 2
show 2 more results
400 mg
covid-19 5.2% (placebo 7%)
injection site reaction 5.2% (placebo 0%)
nasopharyngitis 5.2% (placebo 5.3%)
NCT05256654 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease, Hypertriglyceridemia · phase 2
100 mg
covid-19 13.3% (placebo 7%)
gastroenteritis 10% (placebo 5.3%)
hypertension 6.7% (placebo 3.5%)
NCT05256654 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease, Hypertriglyceridemia · phase 2

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Solbinsiran

Apo B -19% (n=59) vs -11.6% (n=57) placebo @ 25.7wk800 mg
percent change · % of baseline
NCT05256654 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease, Hypertriglyceridemia · phase 2
show 5 more results
-19.4% (n=59) vs -9.5% (n=57) placebo @ 38.6wk800 mg
NCT05256654 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease, Hypertriglyceridemia · phase 2
-24.3% (n=58) vs -11.6% (n=57) placebo @ 25.7wk400 mg
NCT05256654 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease, Hypertriglyceridemia · phase 2
-19.7% (n=58) vs -9.5% (n=57) placebo @ 38.6wk400 mg
NCT05256654 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease, Hypertriglyceridemia · phase 2
-14.1% (n=30) vs -11.6% (n=57) placebo @ 25.7wk100 mg
NCT05256654 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease, Hypertriglyceridemia · phase 2
-19.2% (n=30) vs -9.5% (n=57) placebo @ 38.6wk100 mg
NCT05256654 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease, Hypertriglyceridemia · phase 2
LDL-C -19.7% (n=59) vs -8.7% (n=57) placebo @ 25.7wk800 mg
percent change · % of baseline
NCT05256654 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease, Hypertriglyceridemia · phase 2
show 5 more results
-17.5% (n=59) vs -12.7% (n=57) placebo @ 38.6wk800 mg
NCT05256654 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease, Hypertriglyceridemia · phase 2
-24% (n=58) vs -8.7% (n=57) placebo @ 25.7wk400 mg
NCT05256654 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease, Hypertriglyceridemia · phase 2
-21% (n=58) vs -12.7% (n=57) placebo @ 38.6wk400 mg
NCT05256654 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease, Hypertriglyceridemia · phase 2
-9.9% (n=30) vs -8.7% (n=57) placebo @ 25.7wk100 mg
NCT05256654 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease, Hypertriglyceridemia · phase 2
-7.1% (n=30) vs -12.7% (n=57) placebo @ 38.6wk100 mg
NCT05256654 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease, Hypertriglyceridemia · phase 2
HDL-C -19.4% (n=59) vs 4.3% (n=57) placebo @ 25.7wk800 mg
percent change · % of baseline
NCT05256654 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease, Hypertriglyceridemia · phase 2
show 5 more results
-10.9% (n=59) vs 1.5% (n=57) placebo @ 38.6wk800 mg
NCT05256654 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease, Hypertriglyceridemia · phase 2
-12.8% (n=58) vs 4.3% (n=57) placebo @ 25.7wk400 mg
NCT05256654 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease, Hypertriglyceridemia · phase 2
-7.3% (n=58) vs 1.5% (n=57) placebo @ 38.6wk400 mg
NCT05256654 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease, Hypertriglyceridemia · phase 2
-2.1% (n=30) vs 4.3% (n=57) placebo @ 25.7wk100 mg
NCT05256654 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease, Hypertriglyceridemia · phase 2
-1.9% (n=30) vs 1.5% (n=57) placebo @ 38.6wk100 mg
NCT05256654 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease, Hypertriglyceridemia · phase 2
Non-HDL-C -31.5% (n=59) vs -10.2% (n=57) placebo @ 25.7wk800 mg
percent change · % of baseline
NCT05256654 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease, Hypertriglyceridemia · phase 2
show 5 more results
-27.3% (n=59) vs -9.8% (n=57) placebo @ 38.6wk800 mg
NCT05256654 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease, Hypertriglyceridemia · phase 2
-33.1% (n=58) vs -10.2% (n=57) placebo @ 25.7wk400 mg
NCT05256654 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease, Hypertriglyceridemia · phase 2
-27.6% (n=58) vs -9.8% (n=57) placebo @ 38.6wk400 mg
NCT05256654 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease, Hypertriglyceridemia · phase 2
-19.8% (n=30) vs -10.2% (n=57) placebo @ 25.7wk100 mg
NCT05256654 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease, Hypertriglyceridemia · phase 2
-13.5% (n=30) vs -9.8% (n=57) placebo @ 38.6wk100 mg
NCT05256654 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease, Hypertriglyceridemia · phase 2
Triglycerides -59.7% (n=59) vs -15.1% (n=57) placebo @ 25.7wk800 mg
percent change · % of baseline
NCT05256654 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease, Hypertriglyceridemia · phase 2
show 5 more results
-52.5% (n=59) vs -13.9% (n=57) placebo @ 38.6wk800 mg
NCT05256654 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease, Hypertriglyceridemia · phase 2
-57.8% (n=58) vs -15.1% (n=57) placebo @ 25.7wk400 mg
NCT05256654 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease, Hypertriglyceridemia · phase 2
-50.5% (n=58) vs -13.9% (n=57) placebo @ 38.6wk400 mg
NCT05256654 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease, Hypertriglyceridemia · phase 2
-45.9% (n=30) vs -15.1% (n=57) placebo @ 25.7wk100 mg
NCT05256654 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease, Hypertriglyceridemia · phase 2
-38.3% (n=30) vs -13.9% (n=57) placebo @ 38.6wk100 mg
NCT05256654 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease, Hypertriglyceridemia · phase 2

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: CTX310's landscape · Solbinsiran's landscape